Our mission is to improve the lives of CNS patients.
We developed an unbiased platform that seamlessly combines target discovery, patient stratification, and preclinical screening to find whole-body treatments even for diseases traditionally thought of as focused on the brain. By combining transcriptome data with our proprietary maps of human health, we identify similar patient groups based on network signatures and matching them with compounds that reverse disease. We then harness powerful, on-demand models of disease to rapidly find compounds that work. Our target-agnostic approach results in whole-body treatments for molecularly-defined patient populations using efficacy metrics patients care about.
We systematically find effective therapeutic targets and patients that respond using disease maps and RNA data.
We developed an unbiased platform that seamlessly combines target discovery, patient stratification, and preclinical screening to find whole-body treatments even for diseases traditionally thought of as focused on the brain. By combining transcriptome data with our proprietary maps of human health, we identify similar patient groups based on network signatures and matching them with compounds that reverse disease. We then harness powerful, on-demand models of disease to rapidly find compounds that work. Our target-agnostic approach results in whole-body treatments for molecularly-defined patient populations using efficacy metrics patients care about.
We systematically find effective therapeutic targets and patients that respond using disease maps and RNA data.
We can't do this alone.
|
We are committed to getting patients effective drugs the fastest way possible. We partner with discovery companies to amplify their strengths through cost-effective decision-making in the areas of target discovery, mechanism identification, drug optimization, and patient stratification for small molecules and biologics.
|